PMAM
NKTR icon

Picton Mahoney Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Picton Mahoney Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-183
Closed -$3K – 922
2024
Q2 		$3K Buy
+183
New +$3.86K ﹤0.01% 550

Other funds holding NKTR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Picton Mahoney Asset Management's NKTR Position: Q3 2024 in Review

Picton Mahoney Asset Management sold out of Nektar Therapeutics (NKTR) in Q3 2024, closing a stake of 183 shares — an estimated $3K sold.

Picton Mahoney Asset Management first reported a position in NKTR in Q2 2024 and held it in 1 quarter. The position peaked at $3K in Q2 2024. 138 funds tracked by Wall St. Rank hold NKTR as of Q3 2024.

  • Picton Mahoney Asset Management reported no remaining Nektar Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Picton Mahoney Asset Management sold 183 Nektar Therapeutics shares in Q3 2024, an estimated $3K.
  • Picton Mahoney Asset Management first reported a position in Nektar Therapeutics in Q2 2024 and held it in 1 quarter.
  • Picton Mahoney Asset Management's Nektar Therapeutics position peaked at $3K in Q2 2024.
  • 138 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2024.

Based on Picton Mahoney Asset Management's 13F filing for Q3 2024, filed 4 Nov 2024.